how would MNTA know whether TEVA infringed their patents in characterizing lovenox?
Well, MNTA essentially drafted the FDA requirements for approvability set forth in #msg-52582225 to coincide with MNTA’s patent estate on Lovenox characterization. So it would be a good bet that any approved product would be infringing MNTA’s patents.
To reiterate, I don’t think this angle will ever actually come into play.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.